MedCity News February 5, 2025
Novo Nordisk’s monlunabant showed signs of neuropsychiatric side effects in a mid-stage diabetic kidney disease study, despite a drug design intended to favor hitting its target receptor in peripheral tissues rather than the brain. Neuro effects were also reported last year in a Phase 2 test of this pill in obesity.
A drug that Novo Nordisk acquired to expand its prospects in metabolic disorders has failed a mid-stage clinical trial in diabetic kidney disease. The results also showed signs of a neuropsychiatric side effect that could crimp plans to develop this pill in other metabolic indications, including obesity.
The Phase 2b results for the drug, monlunabant, were tucked into Novo Nordisk’s report of full-year 2024 financial results released Wednesday. The...
Today's Sponsors
Today's Sponsor